OLEMA PHARMACEUTICALS INC

OLMA is the ticker symbol for Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company traded on the Nasdaq exchange. The company focuses on developing oral therapies for women's cancers, including breast cancer. As a clinical-stage company, its value is closely tied to the progress of its drug candidates through clinical trials and regulatory review, rather than to commercial product sales.

Recent performance for OLMA depends on clinical trial updates, regulatory news, and broader biotech market sentiment. For the latest price changes, percentage moves, and volume trends, please refer to the current OLMA quote and performance data displayed on this page. Those figures update regularly and reflect the most current market activity.

Because OLMA is a clinical-stage biopharmaceutical company, traditional metrics such as the price-to-earnings ratio may not apply until it has approved products and earnings. Investors often consider cash position, research and development spending, and pipeline progress instead. Valuation may also reflect expectations for clinical trial success, potential market size for its drug candidates, and the risk of dilution from future financing.

OLMA may be available for trading in pre-market and after-hours sessions through certain brokerage platforms. Extended-hours trading generally has lower liquidity, wider spreads, and higher volatility than the regular Nasdaq session. Not all brokers offer this feature, and orders may not execute if there is insufficient trading interest. Check with your brokerage for specific availability and rules.

Start with OLMA's quarterly and annual filings, such as its 10-Q and 10-K reports, to review cash and cash equivalents, operating expenses, and net loss. For a clinical-stage company, key items include research and development spending, general and administrative costs, and how long current cash reserves are expected to fund operations. These figures are found in the financial statements section of the company's reports and on this page.

OLMA faces risks common to clinical-stage biopharmaceutical companies, including the possibility that drug candidates fail in clinical trials or do not receive regulatory approval. Other risks include relying on external financing, potential dilution from equity raises, competition from larger pharmaceutical companies, and dependence on key personnel. The company may also be affected by changes in healthcare policy, reimbursement rules, and the broader economic environment.